Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

ZYDUSLIFE is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 17.843807
debtToEquity 0.789000
earningsGrowth 0.304000
revenueGrowth 0.170000
grossMargins 0.711520
operatingMargins 0.185230
trailingEps 44.990000
forwardEps 0.000000

Zydus Lifesciences Limited's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
Zydus Lifesciences Limited's positive earnings and revenue growth signal that the company is expected to expand its business. The company's increasing profits and sales reflect strong financial health, suggesting continued growth and success in the coming periods.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Over time, ZYDUSLIFE's price projections have consistently been revised lower. This downward shift suggests analysts are becoming more cautious about the company's future, possibly due to emerging risks or challenges.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


5 ZYDUSLIFE transactions were recorded, when the market price was 999.05.During the period under consideration, there were no sell transactions.More buys than sells near the current price levels of Zydus Lifesciences Limited might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


ZYDUSLIFE has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as ZYDUSLIFE is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.